Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Oncol Rep. 2011 Feb;13(1):42-9. doi: 10.1007/s11912-010-0144-x.

Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.

Author information

1
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. galanis.evanthia@mayo.edu

Abstract

Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.

PMID:
21125354
PMCID:
PMC3155285
DOI:
10.1007/s11912-010-0144-x
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center